Home Business EO Launches First-Ever Digital Health Platform Offering Affordable, Clinician-Guided Cannabis Care

EO Launches First-Ever Digital Health Platform Offering Affordable, Clinician-Guided Cannabis Care

Dave Batista - EO Care

EO Care, Inc. a digital health company focused on cannabinoid-based treatments, recently announced the launch of a new, HIPAA-compliant service and technology platform to meet the need for scalable, affordable, data-informed cannabis care with ongoing clinical oversight.

Combining a powerful patient companion app and proprietary data model/clinician enablement platform, EO is built to provide those suffering from chronic pain, sleeplessness and anxiety with a more responsible, complete and ongoing cannabis care partnership – at a fraction of the cost of current cannabis clinician and dispensary-based care. At the same time, EO provides healthcare leaders, researchers and regulators with an easy-to-deploy platform through which they can better understand and responsibly pilot cannabis-based treatments. 

With an EO subscription, a member can:

  • Define and maintain a personalized cannabis care plan specifying products, doses, and times of use – all overseen by an expert, licensed EO clinician.
  • Message a clinician at any time and schedule one-on-one telehealth consultations.
  • Save money each month on the cannabis products that are working best for them.
  • Have those products delivered to their door via EO’s retail and delivery partners.

Until now, the technologies required to make a responsible, enduring patient-clinician partnership a practical, affordable reality for either party had yet to be developed or deployed. Patients have too often been forced to “go it alone” when attempting to define their optimal cannabis care regimen. At the same time, there’s been no good way for healthcare networks, payers and regulators to responsibly research and pilot cannabinoid-based treatments.

Toward this end, EO’s data focus is on understanding the impact of guided cannabis care on broadly accepted measures of well-being, activities of daily living, patient satisfaction and cost of care, and on enabling ready comparison to other substance-based medical treatments (such as opioid, NSAID, benzodiazepine, Z-drug, and SSRI-based care). 

EO’s CEO is Sean Collins, a longtime leader in the field of guidance and advice platforms. Board members and investors include Bill Van Faasen, past Chairman and CEO of Blue Cross/Blue Shield of Massachusetts and Steve Hoffman, former Chairman of the Massachusetts Cannabis Control Commission.

Age and location-eligible patients can learn more and subscribe at eo.care.